[Role of the combination of trastuzumab and taxanes in the therapeutic management of cancer of the breast: from preclinical data to clinical application].

Date publication

juillet 2003

Journal

Bulletin du cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Pr FUMOLEAU Pierre , Pr MERLIN Jean-Louis

Tous les auteurs :
Campone M, Merlin JL, Fumoleau P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/12957803

Résumé

Taxanes are major drugs in the treatment of breast metastatic cancer. Since 1990, the mechanisms implicated in carcinogenesis are better understood and the oncoprotein HER2 is a potential target. Trastuzumab is a monoclonal antibody that binds to this transmembrane glycoprotein. This antibody demonstrated a significant activity in clinical trials. In this review, we discuss the preclinical (mechanisms of action) and clinical data with the combination of trastuzumab and taxanes.

Mots clés

Antibodies, Monoclonal, administration & dosage, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Breast Neoplasms, drug therapy, Cisplatin, administration & dosage, Drug Screening Assays, Antitumor, Female, Humans, Neoadjuvant Therapy, Paclitaxel, administration & dosage, Prospective Studies, Randomized Controlled Trials as Topic, Receptor, ErbB-2, physiology, Taxoids, Trastuzumab

Référence

Bull Cancer. 2003 Jul;90(7):614-22